Literature DB >> 14974089

BTK: 22 novel and 25 recurrent mutations in European patients with X-linked agammaglobulinemia.

Maurilia Fiorini1, Roberta Franceschini, Annarosa Soresina, Richard-Fabian Schumacher, Alberto G Ugazio, Paolo Rossi, Alessandro Plebani, Luigi D Notarangelo.   

Abstract

X linked agammaglobulinemia (XLA) is an immunodeficiency disease caused by mutations in the gene coding for Bruton's agammaglobulinemia tyrosine kinase (BTK), that is involved in signal transduction pathways regulating survival, activation, proliferation, and differentiation of B lineage lymphoid cells. XLA is a primary immunodeficiency disorder characterized by lack of mature, circulating B lymphocytes, and recurrent infections. Using Single Strand Conformation Polymorphism (SSCP) followed by direct sequencing we investigated 57 patients with XLA phenotype, with or without a positive family history, from 52 unrelated families enrolled in the Italian XLA Multicenter Clinical Study. We have identified 25 recurrent mutations, 22 novel mutations including one large deletion comprising the coding sequence from exon 11 to 18. Among the mutations identified, three were detected in different unrelated families, whereas all the others were private mutations. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14974089     DOI: 10.1002/humu.9219

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

1.  Types and effects of protein variations.

Authors:  Mauno Vihinen
Journal:  Hum Genet       Date:  2015-01-24       Impact factor: 4.132

2.  Four novel and three recurrent mutations of the BTK gene and pathogenic effects of putative splice mutations.

Authors:  Duangrurdee Wattanasirichaigoon; Suwat Benjaponpitak; Chonnamet Techasaensiri; Wasu Kamchaisatian; Pakit Vichyanond; Sucheela Janwityanujit; Lulin Choubtum; Sayomporn Sirinavin
Journal:  J Hum Genet       Date:  2006-09-02       Impact factor: 3.172

3.  Severe combined immunodeficiency (SCID) and attention deficit hyperactivity disorder (ADHD) associated with a Coronin-1A mutation and a chromosome 16p11.2 deletion.

Authors:  Lawrence R Shiow; Kenneth Paris; Matthew C Akana; Jason G Cyster; Ricardo U Sorensen; Jennifer M Puck
Journal:  Clin Immunol       Date:  2008-12-20       Impact factor: 3.969

Review 4.  The mucolipin-2 (TRPML2) ion channel: a tissue-specific protein crucial to normal cell function.

Authors:  Math P Cuajungco; Joshua Silva; Ania Habibi; Jessica A Valadez
Journal:  Pflugers Arch       Date:  2015-09-04       Impact factor: 3.657

Review 5.  Splice-correction strategies for treatment of X-linked agammaglobulinemia.

Authors:  Burcu Bestas; Janne J Turunen; K Emelie M Blomberg; Qing Wang; Robert Månsson; Samir El Andaloussi; Anna Berglöf; C I Edvard Smith
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

6.  Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10-year experience in Auckland, New Zealand.

Authors:  See-Tarn Woon; Rohan Ameratunga
Journal:  Allergy Asthma Clin Immunol       Date:  2016-12-07       Impact factor: 3.406

Review 7.  SH2 domains: modulators of nonreceptor tyrosine kinase activity.

Authors:  Panagis Filippakopoulos; Susanne Müller; Stefan Knapp
Journal:  Curr Opin Struct Biol       Date:  2009-11-18       Impact factor: 6.809

8.  Clinical and mutational features of Vietnamese children with X-linked agammaglobulinemia.

Authors:  Quang Van Vu; Taizo Wada; Huong Thi Minh Le; Hai Thanh Le; Anh Thi Van Nguyen; Ohara Osamu; Akihiro Yachie; Sang Ngoc Nguyen
Journal:  BMC Pediatr       Date:  2014-05-28       Impact factor: 2.125

9.  Uncovering Low-Level Maternal Gonosomal Mosaicism in X-Linked Agammaglobulinemia: Implications for Genetic Counseling.

Authors:  Jacques G Rivière; Clara Franco-Jarava; Mónica Martínez-Gallo; Aina Aguiló-Cucurull; Laura Blasco-Pérez; Ida Paramonov; María Antolín; Andrea Martín-Nalda; Pere Soler-Palacín; Roger Colobran
Journal:  Front Immunol       Date:  2020-02-12       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.